BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 15310398)

  • 1. Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study.
    Chintamani ; Singhal V; Singh JP; Lyall A; Saxena S; Bansal A
    BMC Cancer; 2004 Aug; 4():48. PubMed ID: 15310398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma.
    Chang J; Ormerod M; Powles TJ; Allred DC; Ashley SE; Dowsett M
    Cancer; 2000 Dec; 89(11):2145-52. PubMed ID: 11147583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
    Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
    Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
    Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
    J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.
    Cameron DA; Gregory WM; Bowman A; Anderson ED; Levack P; Forouhi P; Leonard RC
    Br J Cancer; 2000 Jul; 83(1):98-103. PubMed ID: 10883676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy in locally advanced breast cancer.
    Singh G; Singh DP; Gupta D; Muralikrishna BV
    J Surg Oncol; 1996 Jan; 61(1):38-41. PubMed ID: 8544458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
    Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
    Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.
    Sataloff DM; Mason BA; Prestipino AJ; Seinige UL; Lieber CP; Baloch Z
    J Am Coll Surg; 1995 Mar; 180(3):297-306. PubMed ID: 7874340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
    Viens P; Palangié T; Janvier M; Fabbro M; Roché H; Delozier T; Labat JP; Linassier C; Audhuy B; Feuilhade F; Costa B; Delva R; Cure H; Rousseau F; Guillot A; Mousseau M; Ferrero JM; Bardou VJ; Jacquemier J; Pouillart P
    Br J Cancer; 1999 Oct; 81(3):449-56. PubMed ID: 10507769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast conservation after induction chemotherapy for locally advanced breast cancer.
    Kling KM; Ostrzega N; Schmit P
    Am Surg; 1997 Oct; 63(10):861-4. PubMed ID: 9322658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
    Botti C; Vici P; Lopez M; Scinto AF; Cognetti F; Cavaliere R
    J Am Coll Surg; 1995 Sep; 181(3):202-8. PubMed ID: 7670678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy for Chinese women with locally advanced breast cancer.
    Chow LW; Day W; Ng KC
    Am Surg; 2001 May; 67(5):412-6. PubMed ID: 11379638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose- intensified, preoperative and adjuvant chemotherapy in patients with T3- and T4- breast cancer: toxicity, clinical and pathological remission.
    Blohmer JU; Paepke S; Kissner L; Elling D; Fleige B; Grineisen Y; Lichtenegger W
    Zentralbl Gynakol; 1999; 121(11):522-5. PubMed ID: 10612219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of BCL-2 protein in carcinoma of the breast and its clinical correlation in locally advanced breast cancer.
    Aggarwal H; Lubana PS; Jain DK; Mathur RK
    J Cancer Res Ther; 2007; 3(4):207-10. PubMed ID: 18270395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of neoadjuvant chemotherapy +/- letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial.
    Mohammadianpanah M; Ashouri Y; Hoseini S; Amadloo N; Talei A; Tahmasebi S; Nasrolahi H; Mosalaei A; Omidvari S; Ansari M; Mosleh-Shirazi MA
    Breast Cancer Res Treat; 2012 Apr; 132(3):853-61. PubMed ID: 22002564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
    Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of neo-adjuvant chemotherapy in locally advanced breast cancer.
    Akhtar M; Akulwar V; Kulkarni A; Bansal A
    Indian J Cancer; 2015; 52(3):286-9. PubMed ID: 26905112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.